Jemperli trial continues to show positive results for deficient (dMMR) rectal cancer

Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response

Takeda appoints Annapurna Das as the General Manager, India Operations

Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines

Nucala approved in China for use in severe asthma with an eosinophilic phenotype

Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data

New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence

A new GSK survey shows a large number of adults do not understand how shingles may be triggered

Advent International announces the completion of the acquision of Suven Pharma

New Board of Directors and management team at Suven Pharma also appointed

Cenexi appoints Jim McPherson as CEO

Prior to this, Jim held leadership positions at several companies, including Centrient Pharmaceuticals, Leo Pharmaceuticals, Sandoz, Xellia, and GSK

CureVac highlights shift to mRNA technology in seasonal influenza vaccine development: GlobalData

CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology

Ojjaara approved in the US as the first and only treatment for myelofibrosis patients with anaemia

Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy

Biocon Biologics announces leadership appointments

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy